Cost-effectiveness of breast cancer screening policies in Mexico;Costo-efectividad de políticas para el tamizaje de cáncer de mama en México

Salud Publica de Mexico

Volumn 51, Issue SUPPL.2, 2009, Pages

  Valencia Mendoza, Atanacio ^a   Sánchez González, Gilberto ^a   Bautista Arredondo, Sergio ^a   Torres Mejía, Gabriela ^a   Bertozzi, Stefano M ^a,b  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast neoplasms; Cost effectiveness evaluation; Diagnosis; Mexico

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE POLICY; HUMAN; MASS SCREENING; MEXICO; MIDDLE AGED; PROBABILITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH POLICY; HUMANS; MARKOV CHAINS; MASS SCREENING; MEXICO; MIDDLE AGED;

EID: 76049121513     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: 10.1590/S0036-36342009000800020     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108.
2. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005;34(2):405-412.
3. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137(5 part 1):347-360.
4. Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med 2003;348(17):1672-1680.
5. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005;353(17):1773-1783. [Epub 2005 Sep 16].
6. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353(17):1784-1792.
7. Saltzmann P, Kerlikowske K, Phillips K. Cost effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997;127(11):955-965.
8. Arveux P, Wait S, Schaffer P. Building a model to determine the cost-effectiveness of breast cancer screening in France. Eur J Cancer Care (Engl) 2003;12(2):143-153.
9. International Agency for Research on Cancer. Breast Cancer Screening. IARC. Handbooks of Cancer Prevention, vol. 7. Lyon: IARC Press, 2002.
10. Advisory Committee on Breast Cancer Screening. Screening for breast cancer in England: past and future. NHSBSP Publication No 61. February 2006. Typeset by Prepress Projects Ltd, Perth. [Consultado: octubre 2008]. Disponible en: www.prepress-projects.co.uk.
11. Moss S, Blanks R. Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS breast screening programme. J Epidemiol Community Health 1998;52(2):111-115.
12. Andersen MR, Urban N, Ramsey S, Briss PA. Examining the cost-effectiveness of cancer screening promotion. Cancer 2004;101(Suppl 5):1229-1238.
13. Oortmarssen GJ, Habbema JD, van der Maas PJ, de Koning HJ, Collette HJ, Verbeek AL, et al. A model for breast cancer screening. Cancer 1990;66(7):1601-1612.
14. Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS, et al. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med 2001;20(Suppl 3):36-43.
15. Gram. JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998;19:125-152.
16. Consejo Nacional de Población. República Mexicana: Población a mitad de año por sexo y edad, 2005-2050. [Consultado: enero 2008]. Disponible en: http://www.conapo.gob.mx/00cifras/proy/RM.xls.
17. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S. Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res 2008;10(3):R41. [Epub 2008 May 8.]
18. Bassol S. La edad de la menopausia en México. Rev Endocrinol Nut 2006; 14(3):133-136.
19. Chan GS, Ho GH, Yeo AW, Wong CY. Correlation between breast tumour size and level of axillary lymph node involvement. Asian J Surg 2005;28(2):97-99.
20. Schneider C, Fehr MK, Steiner RA, Hagen D, Haller U, Fink D. Frequency and distribution pattern of distant metastases in breast cancer patients at the time of primary presentation. Arch Gynecol Obstet 2003;269(1):9-12.
21. Flores-Luna L, Salazar-Martínez E, Duarte-Torres RM, Torres-Mejía G, Alonso-Ruiz P, Lazcano-Ponce E. Factores pronósticos relacionados con la supervivencia del cáncer de mama. Salud Publica Mex 2008;50:119-125.
22. Consejo Nacional de Población. República Mexicana: Probabilidades de fallecer por sexo y edad, 2005-2050. [Consultado: enero 2008]. Disponible en: http://www.conapo.gob.mx/00cifras/proy/RM.xls.
23. Secretaría de salud. Dirección General de Información en Salud. Bases de datos del SINAIS. [Consultado: agosto 2008]. Disponible en: http://sinais.salud.gob.mx.
24. Organización Mundial de la Salud (OMS). Eligiendo intervenciones que son costo efectivas, umbrales de costo efectividad. [Consultado: octubre 2008]. Disponible en: http://www.who.int/choice/costs/CER_thresholds/en/index.html.
25. Laxminarayan R, Chow J, Shahid-Salles SA. Intervention Cost-Effectiveness: Overview of Main Messages. In: Jamison DT (eds). Disease control priorities in developing countries. 2nd ed. Oxford: Oxford University Press, 2006:35-86.